Statement of Changes in Beneficial Ownership (4)

FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Diamantis Christopher Eric	2. Issuer Name and Ticker or Trading Symbol Rennova Health, Inc. [ RNVA ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director _____ 10% Owner _____ Officer (give title below) __X__ Other (specify below) Former 10% Owner
(Last) (First) (Middle) 1143 GLENDALE LANE	3. Date of Earliest Transaction (MM/DD/YYYY) 9/17/2021
(Street) NASHVILLE, TN 37204 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock ⁽¹⁾								95450000	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrants to Purchase Common Stock	$0.007							8/27/2021 ⁽²⁾	8/27/2024	Common Stock	47500000		47500000	D
Series M Convertible Redeemable Preferred Stock	⁽³⁾							⁽²⁾	⁽²⁾	Common Stock	⁽³⁾		20180	D

Explanation of Responses:
(1)	This Form 4 is being filed to reflect the fact that, as of September 17, 2021, Mr. Diamantis beneficially owned less than 10% of the Common Stock of the Issuer. Mr. Diamantis has not effected any transactions in the securities of the Issuer since the August 27, 2021 Exchange Agreement reported on his prior Form 4. Due to conversions of the Issuer's preferred stock by parties other than Mr. Diamantis, the Issuer's outstanding Common Stock has increased dramatically. As of September 17, 2021, there were 1,057,349,999 shares of Common Stock issued and outstanding and, as a result, Mr. Diamantis' beneficial ownership has decreased to below 10%.
(2)	The exercise of the Warrants and the conversion of the Series M Convertible Redeemable Preferred Stock (the "Series M Preferred Stock") are each subject to ownership blockers of 4.99%. As a result, they are not exercisable or convertible as of September 17, 2021. The Series M Preferred Stock has no stated maturity date.
(3)	The conversion price of the Series M Preferred Stock fluctuates with the price of the Common Stock.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Diamantis Christopher Eric 1143 GLENDALE LANE NASHVILLE, TN 37204				Former 10% Owner

Signatures
/s/ Christopher E. Diamantis		9/30/2021
^**Signature of Reporting Person		Date

Rennova Health (PK) (USOTC:RNVA)
Historical Stock Chart
From Jul 2022 to Aug 2022

Rennova Health (PK) (USOTC:RNVA)
Historical Stock Chart
From Aug 2021 to Aug 2022

RNVA